PT3706739T - Utilização de profármacos de riluzol para tratar ataxias - Google Patents

Utilização de profármacos de riluzol para tratar ataxias

Info

Publication number
PT3706739T
PT3706739T PT188767792T PT18876779T PT3706739T PT 3706739 T PT3706739 T PT 3706739T PT 188767792 T PT188767792 T PT 188767792T PT 18876779 T PT18876779 T PT 18876779T PT 3706739 T PT3706739 T PT 3706739T
Authority
PT
Portugal
Prior art keywords
ataxias
treat
riluzole prodrugs
riluzole
prodrugs
Prior art date
Application number
PT188767792T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66438598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3706739(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of PT3706739T publication Critical patent/PT3706739T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT188767792T 2017-11-12 2018-11-11 Utilização de profármacos de riluzol para tratar ataxias PT3706739T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762584856P 2017-11-12 2017-11-12
US201862717948P 2018-08-13 2018-08-13

Publications (1)

Publication Number Publication Date
PT3706739T true PT3706739T (pt) 2024-12-04

Family

ID=66438598

Family Applications (2)

Application Number Title Priority Date Filing Date
PT188767792T PT3706739T (pt) 2017-11-12 2018-11-11 Utilização de profármacos de riluzol para tratar ataxias
PT241998491T PT4483956T (pt) 2017-11-12 2018-11-11 Troriluzol para utilização no tratamento de ataxia espinocerebelar tipo 3 (sca3)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT241998491T PT4483956T (pt) 2017-11-12 2018-11-11 Troriluzol para utilização no tratamento de ataxia espinocerebelar tipo 3 (sca3)

Country Status (26)

Country Link
US (3) US20210023061A1 (https=)
EP (4) EP4483956B1 (https=)
JP (2) JP7352542B2 (https=)
KR (2) KR20200103658A (https=)
CN (1) CN112292127A (https=)
AU (1) AU2018364749C1 (https=)
BR (1) BR112020009173A2 (https=)
CA (1) CA3082096A1 (https=)
DK (2) DK3706739T3 (https=)
ES (1) ES2996892T3 (https=)
FI (2) FI3706739T3 (https=)
HR (1) HRP20241675T1 (https=)
HU (1) HUE070302T2 (https=)
IL (1) IL274532B2 (https=)
LT (2) LT3706739T (https=)
MD (1) MD3706739T2 (https=)
MX (2) MX2020004678A (https=)
PH (1) PH12020550583A1 (https=)
PL (1) PL3706739T3 (https=)
PT (2) PT3706739T (https=)
RS (1) RS66277B1 (https=)
SG (1) SG11202004332XA (https=)
SI (1) SI3706739T1 (https=)
SM (1) SMT202500022T1 (https=)
WO (1) WO2019094851A1 (https=)
ZA (1) ZA202002626B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140879A1 (en) 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
WO2018031707A1 (en) 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity
US20250127789A1 (en) * 2021-11-04 2025-04-24 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2023230451A2 (en) * 2022-05-23 2023-11-30 Biohaven Therapeutics Ltd. Methods of treating spinocerebellar ataxias
WO2026078657A1 (en) 2024-10-10 2026-04-16 Biohaven Therapeutics Ltd. Prodrugs of riluzole

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
PT1001748E (pt) 1997-07-25 2006-08-31 Alpex Pharma Sa Um processo para a preparacao de um granulado adequado para a preparacao de comprimidos rapidamente desintegraveis na boca
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
ES2292848T3 (es) 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
AU2003211051A1 (en) 2002-02-13 2003-09-04 Michael K. Weibel Drug dose-form and method of manufacture
ATE337003T1 (de) * 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
WO2009146031A1 (en) * 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
US8414356B2 (en) 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8613937B2 (en) 2008-10-31 2013-12-24 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use

Also Published As

Publication number Publication date
JP7352542B2 (ja) 2023-09-28
HUE070302T2 (hu) 2025-05-28
US20230355592A1 (en) 2023-11-09
KR20200103658A (ko) 2020-09-02
EP4699619A3 (en) 2026-05-06
RS66277B1 (sr) 2025-01-31
US20210023061A1 (en) 2021-01-28
PH12020550583A1 (en) 2021-05-31
CA3082096A1 (en) 2019-05-16
ZA202002626B (en) 2025-02-26
LT4483956T (lt) 2026-04-27
JP2021502392A (ja) 2021-01-28
CN112292127A (zh) 2021-01-29
EP4483956A2 (en) 2025-01-01
MD3706739T2 (ro) 2025-02-28
SI3706739T1 (sl) 2025-03-31
US20230390252A1 (en) 2023-12-07
AU2018364749A1 (en) 2020-07-02
WO2019094851A1 (en) 2019-05-16
DK4483956T3 (da) 2026-03-23
FI4483956T3 (fi) 2026-03-16
US12102618B2 (en) 2024-10-01
IL274532A (en) 2020-06-30
DK3706739T3 (da) 2024-12-02
EP4483956A3 (en) 2025-03-19
EP4696324A3 (en) 2026-05-06
PT4483956T (pt) 2026-03-16
PL3706739T3 (pl) 2025-03-10
SG11202004332XA (en) 2020-06-29
JP2023175823A (ja) 2023-12-12
EP4696324A2 (en) 2026-02-18
EP3706739A4 (en) 2021-08-04
EP4483956B1 (en) 2025-12-31
FI3706739T3 (fi) 2024-12-27
MX2023012640A (es) 2023-11-08
EP4699619A2 (en) 2026-02-25
HRP20241675T1 (hr) 2025-02-14
EP3706739B1 (en) 2024-10-16
LT3706739T (lt) 2024-12-27
KR20250034521A (ko) 2025-03-11
NZ765220A (en) 2023-11-24
IL274532B1 (en) 2024-01-01
ES2996892T3 (en) 2025-02-13
AU2018364749C1 (en) 2024-02-15
SMT202500022T1 (it) 2025-03-12
AU2018364749B2 (en) 2023-11-09
EP3706739A1 (en) 2020-09-16
MX2020004678A (es) 2020-08-13
BR112020009173A2 (pt) 2020-11-03
IL274532B2 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
IL274532A (en) Using the prodrug riluzole to treat ataxias
PL3458053T3 (pl) Stosowanie riluzolu, proleków riluzolu lub analogów riluzolu z immunoterapiami w leczeniu nowotworów
IL278080B (en) Riluzole prodrugs and their use
IL283372A (en) Use of cannabinoids in the treatment of epilepsy
IL278188A (en) Sublingual formulation of riluzole
IL268048A (en) Preparation salts and compounds of 1-methyl-d-tryptophan
ZA201705708B (en) Inhibition of olig2 activity
IL268550B (en) Purification of pleuromotilin
IL259153A (en) Use of proteasome inhibitors to treat ocular disorders
IL266087A (en) Use of itolizumab to reduce cd6 phosphorylation
GB2537419B (en) Accumulation of floating-point values
PT3393517T (pt) Ácido acetilsalicílico para utilização no tratamento de influenza moderada a grave
GB2528112B (en) Improvements relating to inhibition of corrosion
ES3064574T3 (en) Methods of using dantrolene to treat exposure to a neurotoxic agent
PT3689913T (pt) Uso de um inibidor de pcsk9 para tratar a hiperlipidemia
IL253231B (en) Use of bgp15 to treat familial dysautonomia
GB201417348D0 (en) Prodrugs of lxazomib
GB201417347D0 (en) Prodrugs of delanzomib